Key Points
- CEO John Quisel sold 40,000 shares on December 11 at an average price of $93.05 for proceeds of $3,722,000, trimming his stake by 18.88% to 171,828 shares (about $15.99M); the transaction was disclosed in an SEC filing.
- Disc Medicine shares trade around $92 with a 1-year range of $30.82–$99.50 and a $3.47B market cap; the company reported a ($1.77) EPS last quarter (missing estimates) and analysts hold a consensus rating of “Moderate Buy” with an average price target of $120 after several recent upgrades.
Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) CEO John Quisel sold 40,000 shares of the firm's stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $93.05, for a total value of $3,722,000.00. Following the completion of the sale, the chief executive officer directly owned 171,828 shares of the company's stock, valued at approximately $15,988,595.40. The trade was a 18.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Disc Medicine Stock Up 0.2%
IRON stock opened at $92.00 on Tuesday. Disc Medicine, Inc. has a 1-year low of $30.82 and a 1-year high of $99.50. The business's 50 day simple moving average is $86.52 and its 200 day simple moving average is $67.90. The company has a current ratio of 23.45, a quick ratio of 23.45 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $3.47 billion, a PE ratio of -17.20 and a beta of 0.86.
Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported ($1.77) EPS for the quarter, missing analysts' consensus estimates of ($1.48) by ($0.29). As a group, research analysts anticipate that Disc Medicine, Inc. will post -4.07 EPS for the current year.
Analyst Ratings Changes
Several equities research analysts have issued reports on the stock. Cantor Fitzgerald raised their price objective on shares of Disc Medicine from $132.00 to $153.00 and gave the stock an "overweight" rating in a research report on Friday, October 17th. Wedbush lifted their price target on Disc Medicine from $90.00 to $110.00 and gave the stock an "outperform" rating in a report on Friday, October 17th. Truist Financial upped their price objective on Disc Medicine from $86.00 to $114.00 and gave the company a "buy" rating in a report on Monday, November 10th. National Bankshares set a $153.00 target price on Disc Medicine in a report on Friday, October 17th. Finally, Stifel Nicolaus began coverage on shares of Disc Medicine in a research note on Monday, November 3rd. They issued a "buy" rating and a $125.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Disc Medicine has an average rating of "Moderate Buy" and a consensus price target of $120.00.
Get Our Latest Analysis on Disc Medicine
Hedge Funds Weigh In On Disc Medicine
Several hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. grew its holdings in Disc Medicine by 11.1% in the second quarter. JPMorgan Chase & Co. now owns 843,616 shares of the company's stock valued at $44,678,000 after purchasing an additional 84,278 shares during the last quarter. Sio Capital Management LLC grew its stake in Disc Medicine by 287.4% in the 2nd quarter. Sio Capital Management LLC now owns 284,787 shares of the company's stock valued at $15,082,000 after acquiring an additional 211,276 shares during the last quarter. Northern Trust Corp increased its holdings in Disc Medicine by 11.7% during the 1st quarter. Northern Trust Corp now owns 208,813 shares of the company's stock valued at $10,365,000 after acquiring an additional 21,796 shares in the last quarter. Geode Capital Management LLC increased its holdings in Disc Medicine by 4.7% during the 2nd quarter. Geode Capital Management LLC now owns 598,589 shares of the company's stock valued at $31,705,000 after acquiring an additional 26,605 shares in the last quarter. Finally, Bank of Montreal Can raised its position in Disc Medicine by 87.8% during the second quarter. Bank of Montreal Can now owns 10,988 shares of the company's stock worth $582,000 after acquiring an additional 5,137 shares during the last quarter. 83.70% of the stock is owned by hedge funds and other institutional investors.
Disc Medicine Company Profile
(
Get Free Report)
Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
